BIOTA Biosciences Recalls Sterile Curcumin Vials Due to Sterility Concerns
BIOTA Biosciences is recalling sterile curcumin vials because the product lacks assurance of sterility and contains unapproved ingredients.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe severity score per the rubric, particularly given the lack of assurance of sterility in a sterile product.
Plain-English summary
BIOTA Biosciences LLC is recalling Sterile Curcumin, 4mg/mL, 10mL vials. The recall is due to a lack of assurance of sterility and because the product was marketed without an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA). The product contains unapproved Cannabidiol and Curcumin.
The affected product is identified by Lot # 2H071219CCD, 2H0712019CCD, and 2H07122019CCD, with an expiration date of 7/12/2021. The product was distributed nationwide within the United States and in New Zealand.
Consumers and healthcare providers should stop using the product and contact BIOTA Biosciences LLC for further instructions or a refund.
The recalled product
- Product
- Sterile Curcumin, 4mg/mL, 10mL vial
- Manufacturer
- BIOTA Biosciences LLC
- Category
- Drug — Injectable
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot #: 2H071219CCD
- 2H0712019CCD
- 2H07122019CCD
- Exp. Date 7/12/2021
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 5 recalled by BIOTA Biosciences LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 5 products in this recall →Related recalls
Same manufacturer · BIOTA Biosciences LLC
See all →- SevereBIOTA Biosciences Recalls Sterile Curcumin Vials Due to Sterility Concerns
FDA (Drugs) · 2020-07-01
- SevereBiota Biosciences Recalls Sterile Cannabidiol Vials Due to Sterility Concerns
FDA (Drugs) · 2020-07-01
- SevereBIOTA Biosciences Recalls Sterile Cannabidiol and Curcumin Vials
FDA (Drugs) · 2020-07-01
- SevereBIOTA Biosciences Recalls Sterile Cannabidiol Vials for Sterility Concerns
FDA (Drugs) · 2020-07-01
Same hazard · sterility
See all →- HighFDA recalls injectable compounded mixture in single-use syringes
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereFDA Recalls Thymosin Beta-4 Vials Due to Sterility Concerns
FDA (Drugs) · 2020-12-23
- SevereMedaus Recalls Hydroxy B12 Vials Due to Sterility Concerns
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls Thiamine Vials Due to Lack of Sterility Assurance
FDA (Drugs) · 2016-07-20
- SevereKRS Global Biotechnology Recalls Hydroxocobalamin Vials Due to Sterility Concerns
FDA (Drugs) · 2019-10-09
- SevereMedaus Recalls Thiamine Vials Due to Sterility Assurance Concerns
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls Hydroxy B12 Vials Due to Sterility Assurance Concerns
FDA (Drugs) · 2016-07-20